WEISMAN HOWARD J. (Chief Executive Officer) sold 6.3% of their position (44.13K shares) of KUVATRIS THERAPEUTICS, INC. on the open market
Open‑market sale worth $20.6K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 8/30/2023ACC: 0001062993-23-017284
DirectorOfficer· Chief Executive Officer
Since Aug 2022
-44.13K
Net shares
Net seller
$20.6K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
44.13K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−12K
Price / share
$0.49
Trade value
$5.86K
% of position
1.7%
8/28/2023
701.73K→689.73K
Common Stock
Direct
Shares
−9.60K
Price / share
$0.48
Trade value
$4.65K
% of position
1.4%
8/29/2023
689.73K→680.13K
Common Stock
Direct
Shares
−22.54K
Price / share
$0.45
Trade value
$10.05K
% of position
3.3%
8/30/2023
680.13K→657.60K
Total
Net shares
−44.13K
Net value
-$20.56K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/28/2023 | S · Sale | −12K | $0.49 | $5.86K | 1.7% | 701.73K | 689.73K |
| Common Stock Direct | 8/29/2023 | S · Sale | −9.60K | $0.48 | $4.65K | 1.4% | 689.73K | 680.13K |
| Common Stock Direct | 8/30/2023 | S · Sale | −22.54K | $0.45 | $10.05K | 3.3% | 680.13K | 657.60K |
| Total | −44.13K | -$20.56K | ||||||
Derivative Transactions0
No derivative transactions reported